MA29786B1 - Combinaisons pour le traitement du cancer - Google Patents

Combinaisons pour le traitement du cancer

Info

Publication number
MA29786B1
MA29786B1 MA30756A MA30756A MA29786B1 MA 29786 B1 MA29786 B1 MA 29786B1 MA 30756 A MA30756 A MA 30756A MA 30756 A MA30756 A MA 30756A MA 29786 B1 MA29786 B1 MA 29786B1
Authority
MA
Morocco
Prior art keywords
combinations
cancer
treatment
compounds
acetic acid
Prior art date
Application number
MA30756A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Original Assignee
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517386A external-priority patent/GB0517386D0/en
Priority claimed from GB0604114A external-priority patent/GB0604114D0/en
Application filed by Antisoma Res Ltd filed Critical Antisoma Res Ltd
Publication of MA29786B1 publication Critical patent/MA29786B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMBINAISONS DE COMPOSÉS TELS QUE DES COMPOSÉS DE LA CLASSE DE L'ACIDE XANTHÉNONE ACÉTIQUE, COMME L'ACIDE 5,6-DIMÉTHYLXANTHÉNONE-4-ACÉTIQUE (DMXAA), ET DE LIANTS DE FACTEUR DE CROISSANCE DE L'ENDOTHÉLIUM VASCULAIRE, EN PARTICULIER L'ANTICORPS MONOCLONAL AVASTIN¿ (BEVACIZUMAB). CETTE INVENTION CONCERNE PLUS PARTICULIÈREMENT L'UTILISATION DE TELLES COMBINAISONS POUR TRAITER LE CANCER, AINSI QUE DES PRÉPARATIONS PHARMACEUTIQUES COMPRENANT CES COMBINAISONS.
MA30756A 2005-08-26 2008-03-17 Combinaisons pour le traitement du cancer MA29786B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0517386A GB0517386D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
GB0604114A GB0604114D0 (en) 2006-03-02 2006-03-02 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
MA29786B1 true MA29786B1 (fr) 2008-09-01

Family

ID=37429252

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30756A MA29786B1 (fr) 2005-08-26 2008-03-17 Combinaisons pour le traitement du cancer

Country Status (14)

Country Link
US (1) US20100297112A1 (fr)
EP (1) EP1917011A1 (fr)
JP (1) JP2009506019A (fr)
KR (1) KR20080047402A (fr)
AU (1) AU2006283371A1 (fr)
BR (1) BRPI0614965A2 (fr)
CA (1) CA2620436A1 (fr)
EC (1) ECSP088243A (fr)
IL (1) IL189376A0 (fr)
MA (1) MA29786B1 (fr)
NO (1) NO20080649L (fr)
RU (1) RU2404764C2 (fr)
TN (1) TNSN08056A1 (fr)
WO (1) WO2007023302A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP2231147A2 (fr) * 2007-12-13 2010-09-29 Novartis AG Combinaisons d'agents thérapeutiques pour le traitement du cancer
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
AU3822701A (en) * 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004094614A2 (fr) * 2003-04-21 2004-11-04 Archemix Corp. Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
JP2009506019A (ja) 2009-02-12
EP1917011A1 (fr) 2008-05-07
CA2620436A1 (fr) 2007-03-01
RU2404764C2 (ru) 2010-11-27
IL189376A0 (en) 2008-06-05
WO2007023302A1 (fr) 2007-03-01
AU2006283371A1 (en) 2007-03-01
KR20080047402A (ko) 2008-05-28
ECSP088243A (es) 2008-08-29
RU2008111492A (ru) 2009-10-10
TNSN08056A1 (en) 2009-07-14
US20100297112A1 (en) 2010-11-25
BRPI0614965A2 (pt) 2016-09-13
NO20080649L (no) 2008-05-26

Similar Documents

Publication Publication Date Title
MA29786B1 (fr) Combinaisons pour le traitement du cancer
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
PL353750A1 (en) Dosages for treatment with anti-erbb2 antibodies
WO2003020279A3 (fr) Compositions et methodes de traitement anticancereux
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA30891B1 (fr) Nouveaux anticorps anti-proliferation
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
PE20070116A1 (es) Formulacion de anticuerpos estables
MA33387B1 (fr) Polypeptides et procede de traitement
MA29991B1 (fr) Anticorps contre la p-cadherine
MA29528B1 (fr) Agents de fixation
WO2002069886A3 (fr) Proteines modifiees, toxines mises au point et procedes de fabrication de celles-ci
MA30047B1 (fr) Procede destine a traiter une lesion articulaire
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
ATE406156T1 (de) Ajulemische säure zur krebsbehandlung
EA200700467A1 (ru) Композиция из растений (варианты), фармацевтическая композиция на ее основе и способ профилактики и лечения нарушения мочеполовых функций
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
WO2002040702A3 (fr) Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
MA34642B1 (fr) Anticorps dirigé contre le tweak humain et leurs utilisations